M Ventures is the strategic corporate venture capital arm of Merck KGaA, Darmstadt, Germany, founded in 2009 and headquartered in Amsterdam. The firm manages over €600 million across biotechnology and technology investments, focusing on healthcare drug development, life science tools, electronics, frontier technology, and sustainability. M Ventures has completed more than 100 investments since inception, backing companies developing treatments for challenging diseases, cutting-edge R&D and manufacturing tools, next-generation computing and display solutions, and sustainable technologies. The firm takes an active, hands-on approach with portfolio companies, combining strategic and financial objectives to support entrepreneurs from early clinical stages through commercial scale. Notable investments include Nouscom (cancer immunotherapy), LabGenius (AI-driven antibody discovery), Trimtech Therapeutics (neurodegenerative therapies), iOnctura (clinical-stage oncology), Calypso Biotech (immunotherapy), Metalenz (metasurface optics), MemryX (edge AI processors), and Neurable (brain-computer interfaces). M Ventures maintains global offices in the Netherlands, Germany, Israel, and the United States.

Profile auto-generated from public sources — details unverified.